Earlier this week, Pfizer announced it has reached an agreement with the U.S. Government for the purchase of an additional 3.7 million treatment courses of its authorized COVID-19 oral treatment, Paxlovid. This purchase supplements the 20 million treatment courses previously contracted by and already delivered to the U.S. Government. The additional 3.7 million treatment courses are planned for delivery by early 2023, Pfizer stated. Reference Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PFE:
- Warren, Welch tell Pfizer to ‘back off’ price hike for vaccine, STATNews says
- Roche announces collaboration with Pfizer to help patients positive for COVID-19
- Pfizer awarded $1.96B Army contract modification for Paxlovid
- Takeda deal has positive read through for Ventyx, says Piper
- Goldman upgrades Pfizer to Buy on pipeline, new launch upside